Growth Metrics

Emergent BioSolutions (EBS) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $663.1 million.

  • Emergent BioSolutions' Non-Current Debt rose 19.64% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 19.64%. This contributed to the annual value of $663.7 million for FY2024, which is 4864.5% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Non-Current Debt stood at $663.1 million, which was up 19.64% from $667.8 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Debt peaked at $1.0 billion during Q3 2022, and registered a low of $446.5 million during Q4 2023.
  • Over the past 5 years, Emergent BioSolutions' median Non-Current Debt value was $663.7 million (recorded in 2024), while the average stood at $650.9 million.
  • In the last 5 years, Emergent BioSolutions' Non-Current Debt plummeted by 5657.4% in 2023 and then surged by 4939.6% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Debt (Quarter) stood at $809.4 million in 2021, then tumbled by 44.59% to $448.5 million in 2022, then fell by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then fell by 0.09% to $663.1 million in 2025.
  • Its Non-Current Debt stands at $663.1 million for Q3 2025, versus $667.8 million for Q2 2025 and $665.7 million for Q1 2025.